右美托咪定用于防治经皮肾镜术术中寒战的剂量探讨

Optimal dose of dexmedetomidine for prevention of shivering in percutaneous nephrolithotomy

  • 摘要: 目的 探讨盐酸右美托咪定用于防治经皮肾镜术围术期寒战反应的适宜剂量。 方法 选择暨南大学附属东莞医院、暨南大学附属第一医院2016年11月-2017年11月择期在椎管内麻醉下行经皮肾镜手术患者120例,随机分为四组,每组30例,D1、D2、D3组分别在麻醉后给予负荷剂量0.5μg/kg、0.75μg/kg、1.0μg/kg的右美托咪定,输注时间为15 min,然后以0.4μg/(kg·h)的速度持续泵注直至手术结束;对照组(N组)给予0.9%氯化钠注射液输注,记录术中患者的生命体征、寒战分级、Ramsay评分、冲洗液的体积及围术期不良反应。 结果 N组有11人发生不同程度的寒战,其寒战程度达到4级;D1组有8人发生不同程度寒战,其寒战程度也达到了3级。N组及D1组寒战发生率分别为36.7%和26.7%;D2组和D3组寒战发生率分别为6.7%和3.3%,显著低于D1组及N组(P< 0.05),而D2组与D3组间差异无统计学意义(P> 0.05)。泵注药物后D2组5例、D3组6例患者出现心动过缓(HR< 60/min),需要使用0.3 ~ 0.5 mg阿托品;D3组有5例口干;N组和D1组发生寒战未缓解的患者静脉给予50 ~ 100 mg曲马多后有不同程度恶心、呕吐,静脉给予昂丹司琼5 mg。余各组各时间点均无恶心、呕吐,无心动过缓和呼吸抑制。 结论 右美托咪定可有效防止经皮肾镜手术患者术中寒战的发生,其适宜剂量为0.75μg/kg,能够显著降低寒战发生率和严重程度,同时减轻患者焦虑感,提高患者舒适度,无药物不良反应发生,俯卧位时通气无明显影响,为临床药物剂量的选择提供一个良好的参考。

     

    Abstract: Objective To study the optimal dose of dexmedetomidine for prevention and treatment of perioperative shivering in percutaneous nephrolithotomy. Methods One hundred and twenty patients who underwent selective percutaneous nephrolithotomy with spinal anesthesia in Dongguan Hospital Affiliated to Jinan University and the First Affiliated Hospital of Jinan University from November 2016 to November 2017 were randomly divided into four groups, with 30 cases in each group. Patients in D1, D2 and D3 groups received dexmedetomidine at loading doses of 0.5μg/kg, 0.75μg/kg, 1.0μg/kg respectively after anesthesia, and the infusion time was 15 min. Then continuous pump injections were given at speed of 0.4μg/(kg·h) until the end of surgery. While, 0.9% sodium chloride injection was given to the control group. Vital signs, shivering classification, Ramsay score, volume of irrigant and perioperative adverse reactions were recorded. Results Eleven patients experienced grade 4 shivering in group N, and 8 patients experienced grade 3 shivering in group D1. The incidence of shivering in group D2 and group D3 was 6.7% and 3.3%, respectively, which was significantly lower than that in group D1 (36.7%) and group N (26.7%)(P< 0.05, respectively). However, there was no significant difference between D2 and D3 groups (P> 0.05). Five patients in group D2 and 6 patients in group D3 had bradycardia(HR< 60 beats/min), and 0.3-0.5 mg atropine was administered. Five patients had dry mouth in the D3 group. The patients who had shivering in group N and group D1 received intravenous administration of tramadol 50-100 mg, and they had varying degrees of nausea and vomiting, then 5 mg of intravenous ondansetron was given; No nausea and vomiting, bradycardia, respiratory depression was occurred in other patients in each group at all time points. Conclusion Dexmedetomidine can effectively prevent intraoperative shivering in patients undergoing percutaneous nephrolithotomy with the optimal dose of 0.75μg/kg. It can not only reduce the incidence and severity of shivering, but relieve anxiety and improve patient comfort at the same time, without adverse drug reactions and significant impact on ventilation in the prone position.

     

/

返回文章
返回